Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
(ANI or the Company) (Nasdaq: ANIP) today announced that following final approval ... markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its ...